NO985464L - Konsentrert antistoffpreparat - Google Patents
Konsentrert antistoffpreparatInfo
- Publication number
- NO985464L NO985464L NO985464A NO985464A NO985464L NO 985464 L NO985464 L NO 985464L NO 985464 A NO985464 A NO 985464A NO 985464 A NO985464 A NO 985464A NO 985464 L NO985464 L NO 985464L
- Authority
- NO
- Norway
- Prior art keywords
- antibody preparation
- concentrated antibody
- preparation
- concentrated
- disclosed
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Det beskrives et konsentrert antistoffpreparat, farmasøytiske formuleringer inneholdende et slikt preparat, dets anvendelse i human terapi og fremgangsmåter for dets fremstilling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9610992.1A GB9610992D0 (en) | 1996-05-24 | 1996-05-24 | Concentrated antibody preparation |
PCT/EP1997/002595 WO1997045140A1 (en) | 1996-05-24 | 1997-05-22 | Concentrated antibody preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
NO985464D0 NO985464D0 (no) | 1998-11-23 |
NO985464L true NO985464L (no) | 1999-01-18 |
Family
ID=10794316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO985464A NO985464L (no) | 1996-05-24 | 1998-11-23 | Konsentrert antistoffpreparat |
Country Status (28)
Country | Link |
---|---|
US (1) | US6252055B1 (no) |
EP (1) | EP0907378B1 (no) |
JP (1) | JP3338060B2 (no) |
KR (1) | KR20000015935A (no) |
CN (1) | CN1219882A (no) |
AP (1) | AP9801392A0 (no) |
AR (1) | AR007249A1 (no) |
AT (1) | ATE318146T1 (no) |
AU (1) | AU731950B2 (no) |
BR (1) | BR9709267A (no) |
CA (1) | CA2254983A1 (no) |
CO (1) | CO4850562A1 (no) |
CZ (1) | CZ382498A3 (no) |
DE (1) | DE69735295T2 (no) |
EA (1) | EA001860B1 (no) |
ES (1) | ES2258277T3 (no) |
GB (1) | GB9610992D0 (no) |
ID (1) | ID16966A (no) |
IL (1) | IL126940A0 (no) |
IS (1) | IS4892A (no) |
NO (1) | NO985464L (no) |
NZ (1) | NZ332625A (no) |
PE (1) | PE69098A1 (no) |
PL (1) | PL330111A1 (no) |
TR (1) | TR199802423T2 (no) |
WO (1) | WO1997045140A1 (no) |
YU (1) | YU53098A (no) |
ZA (1) | ZA974486B (no) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
CA2371427A1 (en) * | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof |
JP4812228B2 (ja) * | 2000-08-10 | 2011-11-09 | 中外製薬株式会社 | 抗体含有溶液の凝集物生成または白濁抑制方法 |
EP2116265B1 (en) * | 2000-10-12 | 2020-12-23 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US6365395B1 (en) * | 2000-11-03 | 2002-04-02 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
AU2006202688B2 (en) * | 2001-05-31 | 2009-01-22 | Genentech, Inc. | Stable liquid formulations of antibodies |
CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
ES2338218T3 (es) | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
AU2002342151B2 (en) * | 2001-10-26 | 2007-07-19 | Immuno-Rx, Inc. | Immunotherapy for reversing immune suppression |
JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Igg抗体の安定な液体医薬製剤 |
AU2003212912A1 (en) | 2002-02-04 | 2003-09-02 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
CN101066450A (zh) | 2002-02-14 | 2007-11-07 | 中外制药株式会社 | 包含抗体的溶液制剂 |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
AU2012202845B2 (en) * | 2003-02-10 | 2014-09-04 | Biogen Ma Inc. | Immunoglobulin formulation and method of preparation thereof |
PT3417875T (pt) | 2003-02-10 | 2020-08-24 | Biogen Ma Inc | Formulação de imunoglobulinas e método de preparação das mesmas |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
RU2332986C2 (ru) * | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
US20070172475A1 (en) * | 2004-02-12 | 2007-07-26 | Susanne Matheus | Highly concentrated, liquid formulations of anti-egfr antibodies |
WO2005086698A2 (en) * | 2004-03-04 | 2005-09-22 | Mayo Foundation For Medical Education And Research | Methods for altering t cell diversity |
US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
CA2566075A1 (en) * | 2004-05-12 | 2005-12-01 | Baxter Healthcare S.A. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
DK1758558T3 (da) | 2004-05-12 | 2014-01-20 | Baxter Int | Oligonukleotidholdige mikrokugler samt deres anvendelse til fremstilling af et medikament til behandling af diabetes type 1 |
ES2422757T3 (es) | 2004-05-12 | 2013-09-13 | Baxter Int | Uso terapéutico de microesferas de ácido nucleico |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
EP1858552A2 (en) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Composition comprising human igg2 antibody and a chelating agent |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
CA2893252C (en) | 2005-08-24 | 2018-05-29 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
SI1942939T2 (sl) * | 2005-09-30 | 2021-11-30 | Medimmune Limited | Sestavek protitelesa proti interlevkinu-13 |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
BRPI0709726A2 (pt) | 2006-04-05 | 2011-07-26 | Abbott Biotechnology Ltd. | purificaÇço de anticorpo |
WO2008019346A2 (en) | 2006-08-04 | 2008-02-14 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
MX2009010361A (es) | 2007-03-29 | 2009-10-16 | Abbott Lab | Anticuerpos il-12 anti-humanos cristalinos. |
JP5744513B2 (ja) | 2007-04-17 | 2015-07-08 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 肺送達のための核酸微小粒子 |
JP2010532790A (ja) * | 2007-07-06 | 2010-10-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗体処方 |
US8633302B2 (en) | 2007-07-17 | 2014-01-21 | Hoffmann-La Roche Inc. | Variable tangential flow filtration |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20100249384A1 (en) * | 2007-11-29 | 2010-09-30 | Stefan Hepbildikler | Immunoglobulin aggregates |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
BRPI0821600A2 (pt) * | 2007-12-28 | 2015-06-23 | Bioinvent Int Ab | Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo |
AU2009236305B2 (en) | 2008-04-15 | 2014-04-10 | Grifols Therapeutics Inc. | Two-stage ultrafiltration/diafiltration |
AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
JP6159528B2 (ja) * | 2009-03-24 | 2017-07-05 | ワイス・エルエルシー | 高濃縮のタンパク質治療薬を生成するための膜蒸発 |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
WO2011095543A1 (en) | 2010-02-04 | 2011-08-11 | Csl Behring Ag | Immunoglobulin preparation |
EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
CN105001335B (zh) | 2010-03-01 | 2019-10-25 | 拜耳医药保健有限公司 | 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体 |
PT2616090T (pt) | 2010-09-17 | 2023-10-16 | Takeda Pharmaceuticals Co | Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro |
EP2637690B1 (en) | 2010-11-11 | 2016-09-21 | AbbVie Biotechnology Ltd | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS |
CN107115526A (zh) * | 2011-05-02 | 2017-09-01 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
US20130172536A1 (en) * | 2011-08-16 | 2013-07-04 | Shenzhen Weiguang Biological Products Co.,Ltd. | Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof |
TWI610937B (zh) | 2011-08-26 | 2018-01-11 | 巴克斯歐塔公司 | 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法 |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
DK2892550T3 (da) | 2012-09-07 | 2020-03-30 | Coherus Biosciences Inc | Stabile vandige formuleringer af adalimumab |
EP2727602A1 (en) * | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
EP2727643A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions |
CN111202711B (zh) | 2013-09-11 | 2022-06-21 | 伊戈尔生物药品股份有限公司 | 包含有机磷酸酯的液体蛋白质制剂 |
JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
WO2015157286A1 (en) * | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
WO2015168622A1 (en) * | 2014-05-01 | 2015-11-05 | Virginia Tech Intellectual Properties, Inc. | Keratin nanomaterials and methods of production |
EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
WO2017027861A1 (en) | 2015-08-13 | 2017-02-16 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
WO2018075818A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
JP7483679B2 (ja) * | 2018-08-14 | 2024-05-15 | ブリストル-マイヤーズ スクイブ カンパニー | 改善されたタンパク質の回収 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0064210B2 (en) | 1981-05-01 | 1991-03-06 | Miles Inc. | Oral pharmaceutical composition containing immune globulin |
JPH01268646A (ja) * | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
DE4211169C1 (no) * | 1992-03-31 | 1993-06-03 | Klaus Kretzschmar | |
WO1993023556A1 (en) * | 1992-05-08 | 1993-11-25 | Genentech, Inc. | Antibodies to leukemia inhibitory factor |
WO1994015640A1 (en) * | 1993-01-12 | 1994-07-21 | Anthony George Gristina | Methods and compositions for the direct concentrated delivery of passive immunity |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
PT2275119E (pt) * | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
-
1996
- 1996-05-24 GB GBGB9610992.1A patent/GB9610992D0/en active Pending
-
1997
- 1997-05-21 AR ARP970102171A patent/AR007249A1/es not_active Application Discontinuation
- 1997-05-22 EP EP97923962A patent/EP0907378B1/en not_active Revoked
- 1997-05-22 PL PL97330111A patent/PL330111A1/xx unknown
- 1997-05-22 CO CO97028095A patent/CO4850562A1/es unknown
- 1997-05-22 NZ NZ332625A patent/NZ332625A/xx unknown
- 1997-05-22 AT AT97923962T patent/ATE318146T1/de not_active IP Right Cessation
- 1997-05-22 CA CA002254983A patent/CA2254983A1/en not_active Abandoned
- 1997-05-22 DE DE69735295T patent/DE69735295T2/de not_active Expired - Lifetime
- 1997-05-22 CZ CZ983824A patent/CZ382498A3/cs unknown
- 1997-05-22 JP JP54155397A patent/JP3338060B2/ja not_active Expired - Fee Related
- 1997-05-22 WO PCT/EP1997/002595 patent/WO1997045140A1/en active IP Right Grant
- 1997-05-22 ZA ZA974486A patent/ZA974486B/xx unknown
- 1997-05-22 ES ES97923962T patent/ES2258277T3/es not_active Expired - Lifetime
- 1997-05-22 CN CN97194891A patent/CN1219882A/zh active Pending
- 1997-05-22 YU YU53098A patent/YU53098A/sh unknown
- 1997-05-22 US US09/180,485 patent/US6252055B1/en not_active Expired - Lifetime
- 1997-05-22 EA EA199800946A patent/EA001860B1/ru not_active IP Right Cessation
- 1997-05-22 IL IL12694097A patent/IL126940A0/xx unknown
- 1997-05-22 TR TR1998/02423T patent/TR199802423T2/xx unknown
- 1997-05-22 AU AU29589/97A patent/AU731950B2/en not_active Ceased
- 1997-05-22 BR BR9709267A patent/BR9709267A/pt not_active IP Right Cessation
- 1997-05-22 KR KR1019980709489A patent/KR20000015935A/ko not_active Application Discontinuation
- 1997-05-22 AP APAP/P/1998/001392A patent/AP9801392A0/en unknown
- 1997-05-23 ID IDP971722A patent/ID16966A/id unknown
- 1997-05-23 PE PE1997000415A patent/PE69098A1/es not_active Application Discontinuation
-
1998
- 1998-11-10 IS IS4892A patent/IS4892A/is unknown
- 1998-11-23 NO NO985464A patent/NO985464L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP3338060B2 (ja) | 2002-10-28 |
ZA974486B (en) | 1998-11-23 |
WO1997045140A1 (en) | 1997-12-04 |
NZ332625A (en) | 2000-04-28 |
AU731950B2 (en) | 2001-04-05 |
BR9709267A (pt) | 1999-08-10 |
US6252055B1 (en) | 2001-06-26 |
JPH11512753A (ja) | 1999-11-02 |
NO985464D0 (no) | 1998-11-23 |
AP9801392A0 (en) | 1998-12-31 |
CZ382498A3 (cs) | 1999-05-12 |
AR007249A1 (es) | 1999-10-27 |
EA199800946A1 (ru) | 1999-06-24 |
DE69735295D1 (de) | 2006-04-27 |
TR199802423T2 (xx) | 1999-02-22 |
ID16966A (id) | 1997-11-27 |
AU2958997A (en) | 1998-01-05 |
CO4850562A1 (es) | 1999-10-26 |
PL330111A1 (en) | 1999-04-26 |
YU53098A (sh) | 2000-03-21 |
GB9610992D0 (en) | 1996-07-31 |
KR20000015935A (ko) | 2000-03-15 |
EA001860B1 (ru) | 2001-10-22 |
IS4892A (is) | 1998-11-10 |
DE69735295T2 (de) | 2006-10-05 |
CN1219882A (zh) | 1999-06-16 |
ATE318146T1 (de) | 2006-03-15 |
PE69098A1 (es) | 1998-12-02 |
ES2258277T3 (es) | 2006-08-16 |
EP0907378B1 (en) | 2006-02-22 |
CA2254983A1 (en) | 1997-12-04 |
EP0907378A1 (en) | 1999-04-14 |
IL126940A0 (en) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO985464L (no) | Konsentrert antistoffpreparat | |
NO2009028I1 (no) | Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat | |
NO307707B1 (no) | Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav | |
IS4345A (is) | Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur | |
DK0870003T4 (da) | Hydrobehandlingskatalysator: sammensætning, fremstilling og anvendelse deraf | |
NO965103L (no) | Bicykliske aromatiske forbindelser, anvendelse derav, og farmasöytiske og kosmetiske preparater | |
NO974572D0 (no) | Cyklodextrin-forbindelser, fremgangsmåter for fremstilling og anvendelse derav | |
DK0826673T3 (da) | Acetamidderivater, fremgangsmåde til fremstilling deraf og medicinske præparater | |
TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
NO308854B1 (no) | Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav | |
DK0832104T3 (da) | Dolastatinderivater, deres fremstilling og anvendelse | |
DE69828895D1 (de) | Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen | |
ITRM920412A1 (it) | Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico. | |
NO880434D0 (no) | Anestetisk preparat og fremgangsmaate for bruk derav. | |
NO307510B1 (no) | Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav | |
NO975020D0 (no) | Azacykloalkanderivater, fremstilling derav og deres anvendelse i terapi | |
RS49599B (sr) | Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija | |
NO943288L (no) | Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer | |
NO891006D0 (no) | Terapeutisk aktivt polypeptid og fremgangsmaate for dets fremstilling. | |
NO962477L (no) | Benzamidderivater, deres fremstilling og deres terapautiske anvendelse | |
NO931342D0 (no) | Benzimidazoler, medisinske preparater inneholdende disse,og fremgangsmaate for deres fremstilling | |
NO973980D0 (no) | Imiadazolderivater og medisinsk preparat | |
NO326826B1 (no) | Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav | |
DK0835254T3 (da) | Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse | |
TR199801184T2 (xx) | Analjezik tesirli yeni bile�ikler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |